HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

72.300

+0.3500.49%

Volume:1.44M

Turnover:103.17M

Market Cap:14.39B

PE:-51.21

High:73.850

Open:73.850

Low:69.750

Close:71.950

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:0.97

T/O Rate:0.73%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.412

ROE:-27.61%

ROA:-9.92%

PB:9.74

PE(LYR):-51.21

PS:69.57

Loading ...

Overview Company News Filings

Leads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million

Bulletin Express

LEADS BIOLABS-B Awards 2.2547 Million Shares Under H-Share Incentive Scheme

Nanjing Leads Biolabs Grants 2,254,691 H-share Awards Under Employee Incentive Scheme

This Nanjing Leads Biolabs Insider Reduced Their Stake By 40%

Simply Wall St.

Assessing LEADS BIOLABS-B After a 50% Price Drop: H-Share Full Circulation, Early Shareholder Unlock, and Custody Movements

New Energy System Blueprint and Rural EV Initiative Unveiled as Key Stocks Report Earnings

Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-specific T-cell Engager Lbl‑051 for Autoimmune Diseases into Clinical Development

THOMSON REUTERS

Nanjing Leads Biolabs Co - Series B Round Led by Pfizer Ventures with Deep Track Capital, Gv, and Aditum Bio

THOMSON REUTERS

Nanjing Leads Biolabs Says Partner Oblenio Moves Lbl-051 Toward Clinical Trial Start After US$62 Million Series B Financing

Leads Biolabs Completes H-Share Full Circulation, Free-Float Rises to 99.39%

Bulletin Express

Nanjing Leads Biolabs converts 44,391,598 unlisted shares into H shares for HKEX listing

LEADS BIOLABS-B Records HK$1.486 Billion in Deposited Shares as Major Holder Transfers 25.85 Million Shares

Nanjing Leads Biolabs says LBL-024 Phase II first-line NSCLC data wins oral slot at 2026 WCLC

Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme

Bulletin Express

LEADS BIOLABS-B (09887) Authorizes Trustee to Acquire Up to $50 Million Worth of H Shares Under Incentive Plan

Nanjing Leads Biolabs Co Ltd - Instructs Trustee to Buy H Shares up to US$50 Mln Under H Share Award Scheme

THOMSON REUTERS

LEADS BIOLABS-B Surges Over 4% in Morning Trading Following Phase III Clinical Trial Approval for Velishen™

Leads Biolabs Gains CDE Green Light for Phase III Trial of PD-L1/4-1BB Bispecific Antibody in First-Line EP-NEC

Bulletin Express

LEADS BIOLABS-B (09887): Phase 3 Trial for VELIXIN™ (PD-L1/4-1BB Bispecific Antibody Opatumilab) in Advanced Extrapulmonary Neuroendocrine Carcinoma Receives CDE Approval

Nanjing Leads Biolabs wins China CDE clearance for LBL-024 Phase III EP-NEC trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/09887/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":72.3,"timestamp":1788163728010,"preClose":71.95,"halted":0,"volume":1444087,"delay":0,"changeRate":0.004864489228630914,"floatShares":198000000,"shares":199000000,"eps":-1.4116998628257886,"marketStatus":"Not Yet Opened","change":0.35,"latestTime":"08-31 16:08:48","open":73.85,"high":73.85,"low":69.75,"amount":103174580,"amplitude":0.056984,"askPrice":72.3,"askSize":36900,"bidPrice":72.25,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.3731989574759944,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":71.95,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.974167,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-9.92%","roe":"-27.61%","lyrEps":-1.4117,"volumeRatio":0.974167,"shares":199000000,"dividePrice":0,"high":73.85,"amplitude":0.056984,"preClose":71.95,"low":69.75,"week52Low":44.72,"pbRate":"9.74","psRate":"69.57","week52High":97.5,"institutionHeld":0,"latestPrice":72.3,"committee":-0.989218,"eps":-1.4116998628257886,"divideRate":0,"volume":1444087,"delay":0,"ttmEps":-1.3731989574759944,"open":73.85,"prevYearClose":51,"prevWeekClose":71.95,"prevMonthClose":53.4,"prevQuarterClose":49.32,"fiveDayClose":69.05,"twentyDayClose":56.95,"sixtyDayClose":56.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1780243200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-08-28","current":-52.650783,"percent":0.130597,"low":-76.458084,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"high":-30.202688,"avg":-42.108117,"sd":9.834997,"marketCap":14310265010},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160},{"date":"2026-08-28","current":-49.214108,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"marketCap":14310265010}],"updateTime":1788201468920},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1189242408","title":"Leads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1189242408","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189242408?lang=en_us&edition=fundamental","pubTime":"2026-07-02 17:25","pubTimestamp":1782984351,"startTime":"0","endTime":"0","summary":"On 02 July 2026, Nanjing Leads Biolabs Co., Ltd. filed its Monthly Return for the period ended 30 June 2026 with Hong Kong Exchanges and Clearing Limited, detailing a sizeable realignment of its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183498438","title":"LEADS BIOLABS-B Awards 2.2547 Million Shares Under H-Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1183498438","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183498438?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:20","pubTimestamp":1782908424,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced the granting of a total of 2.2547 million share awards under its H-share incentive scheme.The awards were granted to 149 recipients on July 1, 2026, and are subject to acceptance by the grantees to become effective.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252152.HKD","09887","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648051015","title":"Nanjing Leads Biolabs Grants 2,254,691 H-share Awards Under Employee Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2648051015","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648051015?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:45","pubTimestamp":1782906351,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs grants 2,254,691 H-share awards under employee incentive schemeNanjing Leads Biolabs granted 2,254,691 share Awards under its H Share Award Scheme, covering 149 employees.Executi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL8wPBMC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647575581","title":"This Nanjing Leads Biolabs Insider Reduced Their Stake By 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647575581","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647575581?lang=en_us&edition=fundamental","pubTime":"2026-06-30 09:44","pubTimestamp":1782783864,"startTime":"0","endTime":"0","summary":"From what we can see, insiders were net sellers in Nanjing Leads Biolabs Co., Ltd.'s ( HKG:9887 ) during the past 12...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/this-nanjing-leads-biolabs-insider-reduced-their-stake-by-40","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/this-nanjing-leads-biolabs-insider-reduced-their-stake-by-40","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","09887","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119804571","title":"Assessing LEADS BIOLABS-B After a 50% Price Drop: H-Share Full Circulation, Early Shareholder Unlock, and Custody Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1119804571","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119804571?lang=en_us&edition=fundamental","pubTime":"2026-06-26 09:59","pubTimestamp":1782439157,"startTime":"0","endTime":"0","summary":"Since last September, the Hong Kong stock market's innovative drug sector has shifted from its previous bull market state, entering a volatile downtrend, with a particularly persistent decline...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252152.HKD","HK0000500386.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107543120","title":"New Energy System Blueprint and Rural EV Initiative Unveiled as Key Stocks Report Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1107543120","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107543120?lang=en_us&edition=fundamental","pubTime":"2026-06-26 07:26","pubTimestamp":1782429979,"startTime":"0","endTime":"0","summary":"Two major national plans have been announced, focusing on the development of a new energy system by 2030 and a new round of rural new energy vehicle promotion. Key Developments The National...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1615","HK0000306701.USD","HK0000500386.USD","HK0000165453.HKD","HK0000320264.USD","BK1613","BK1500","BK1161","LU1808992512.USD","09887","HK0000252160.HKD","BK1113","09879","BK4588","BK1589","HK0000252152.HKD","BK1512","BK1227","BK1109","00020","BK1502","80020","LU1675838814.USD","HK0000320223.HKD","BK4585","159945","VXUS","02696","03998","BK1574","HK0000306685.HKD","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646874382","title":"Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-specific T-cell Engager Lbl‑051 for Autoimmune Diseases into Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2646874382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646874382?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:38","pubTimestamp":1782383880,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA2BPFC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000500386.USD","09887","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646743858","title":"Nanjing Leads Biolabs Co - Series B Round Led by Pfizer Ventures with Deep Track Capital, Gv, and Aditum Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2646743858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646743858?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:38","pubTimestamp":1782383880,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA2BPFC5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0456855351.SGD","IE00B19Z3581.USD","PFE","BK4588","IE00BLSP4452.SGD","SG9999002224.SGD","HK0000500386.USD","BK4533","BK4550","IE000M9KFDE8.USD","IE00BLSP4239.USD","LU0306807586.USD","LU1066053197.SGD","IE0002270589.USD","LU1066051498.USD","IE00BBT3K403.USD","SG9999013999.USD","LU0289739699.SGD","LU0306806265.USD","LU0985481810.HKD","LU1057294990.SGD","LU1894683348.USD","HK0000252152.HKD","BK4534","BK4592","SG9999001176.SGD","IE00B3T34201.USD","SG9999002232.USD","BK4568","LU0868494617.USD","09887","LU0321505868.SGD","BK4585","SG9999011175.SGD","HK0000252160.HKD","LU0321505439.SGD","LU0225284248.USD","SG9999003800.SGD","IE00B19Z3B42.SGD","LU2596442595.SGD","LU1894683264.USD","BK4007","BK4599","LU0058720904.USD","BK4581","LU1883839398.USD","BK1161","LU0234572021.USD","LU0122379950.USD","LU0170899867.USD","LU0225771236.USD","LU1023059063.AUD","SGXZ57979304.SGD","SG9999001176.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646879406","title":"Nanjing Leads Biolabs Says Partner Oblenio Moves Lbl-051 Toward Clinical Trial Start After US$62 Million Series B Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646879406","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646879406?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:01","pubTimestamp":1782381702,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says partner Oblenio moves LBL-051 toward clinical trial start after US$62 million Series B financingNanjing Leads Biolabs’ partner Oblenio Bio closed an oversubscribed USD 62 mi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL4gVVJq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","09887","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113955695","title":"Leads Biolabs Completes H-Share Full Circulation, Free-Float Rises to 99.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113955695","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113955695?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:04","pubTimestamp":1780661065,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced the successful completion of its H-share full circulation programme, converting 44.39 million previously unlisted domestic shares into H...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641117625","title":"Nanjing Leads Biolabs converts 44,391,598 unlisted shares into H shares for HKEX listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641117625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641117625?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:24","pubTimestamp":1780658645,"startTime":"0","endTime":"0","summary":"Converted 44,391,598 unlisted shares into H shares; conversion completed June 4, 2026.Converted H shares began trading in Hong Kong at 9:00 a.m. on June 5, 2026.H shares rose to 197,670,289 from 153,278,691; stake increased to 99.39% from 77.07%.Unlisted shares fell to 1,221,511 from 45,613,109; stake dropped to 0.61% from 22.93%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL3LzCGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198050083","title":"LEADS BIOLABS-B Records HK$1.486 Billion in Deposited Shares as Major Holder Transfers 25.85 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1198050083","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198050083?lang=en_us&edition=fundamental","pubTime":"2026-06-05 08:26","pubTimestamp":1780619193,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, a significant position change occurred for LEADS BIOLABS-B (09887) on June 4th. The total market value of shares deposited reached...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","161027","BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638651382","title":"Nanjing Leads Biolabs says LBL-024 Phase II first-line NSCLC data wins oral slot at 2026 WCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651382","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638651382?lang=en_us&edition=fundamental","pubTime":"2026-05-28 12:01","pubTimestamp":1779940868,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs said Phase II results for Opamtistomig  in first-line NSCLC will be presented at the 2026 WCLC on Sept. 12-15.The study tested Opamtistomig with chemotherapy, showing strong tumor responses that improved with longer follow-up across key patient subgroups.Safety remained consistent with earlier disclosures, supporting the group’s strategy to position the PD-L1/4-1BB bispecific as a broader oncology platform asset.The company cited more than 600 patients treated across programs, with escalating doses in trials without dose-limiting toxicity reported to date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL104zH9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","BK1161","09887","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158348933","title":"Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1158348933","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158348933?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:22","pubTimestamp":1779276169,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has authorised the trustee of its H Share Award Scheme to buy additional H shares on the open market for an aggregate consideration of up to US$50.00...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153977350","title":"LEADS BIOLABS-B (09887) Authorizes Trustee to Acquire Up to $50 Million Worth of H Shares Under Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1153977350","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153977350?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:20","pubTimestamp":1779276036,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that the company has instructed the trustee to utilize plan funds, with a total maximum amount of $50 million, to acquire additional H shares through open market...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000252160.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636491018","title":"Nanjing Leads Biolabs Co Ltd - Instructs Trustee to Buy H Shares up to US$50 Mln Under H Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2636491018","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636491018?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:12","pubTimestamp":1779275565,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nFWN41X0MR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161159700","title":"LEADS BIOLABS-B Surges Over 4% in Morning Trading Following Phase III Clinical Trial Approval for Velishen™","url":"https://stock-news.laohu8.com/highlight/detail?id=1161159700","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161159700?lang=en_us&edition=fundamental","pubTime":"2026-05-19 10:24","pubTimestamp":1779157465,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) rose more than 4% in morning trading. As of the time of writing, the stock was up 3.21% to HK$64.35, with a turnover of HK$8.9751 million. On the news front, on May 19, LEADS...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1161","VXUS","HK0000252160.HKD","HK0000500386.USD","09887","HK0000252152.HKD","BK4588","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150184251","title":"Leads Biolabs Gains CDE Green Light for Phase III Trial of PD-L1/4-1BB Bispecific Antibody in First-Line EP-NEC","url":"https://stock-news.laohu8.com/highlight/detail?id=1150184251","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150184251?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:22","pubTimestamp":1779146554,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. announced that China’s Center for Drug Evaluation has approved a randomized, double-blind, multi-centre Phase III study of Opamtistomig (LBL-024), a PD-L1/4-1BB...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160449247","title":"LEADS BIOLABS-B (09887): Phase 3 Trial for VELIXIN™ (PD-L1/4-1BB Bispecific Antibody Opatumilab) in Advanced Extrapulmonary Neuroendocrine Carcinoma Receives CDE Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1160449247","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160449247?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:22","pubTimestamp":1779146527,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the initiation of a confirmatory Phase 3 clinical...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1223082196.USD","BK4023","III","CDE","09887","HK0000500386.USD","LU1169590202.USD","LU1223082519.USD","HK0000252152.HKD","BK4134","PD","BK4017","HK0000252160.HKD","LU1223083913.SGD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636800242","title":"Nanjing Leads Biolabs wins China CDE clearance for LBL-024 Phase III EP-NEC trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636800242","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636800242?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:13","pubTimestamp":1779146008,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs secured clearance from China’s NMPA drug evaluator to start a confirmatory Phase III trial of Opamtistomig  with platinum chemotherapy as a first-line treatment for advanced extrapulmonary neuroendocrine carcinoma.The randomized, double-blind study follows Phase Ib/II results that the company plans to present at ESMO this year.A separate single-arm registrational study of Opamtistomig as a third-line-or-later monotherapy is slated for a BLA filing in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 18, 2026, and is solely re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL2pRr1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":139,"code":"91000000","status":"200"}]}}